Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVNNASDAQ:GPCRNASDAQ:SLRNNASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$18.69-6.7%$21.03$15.96▼$30.03$915.89M1.03280,139 shs516,094 shsGPCRStructure Therapeutics$15.12-7.4%$23.03$14.88▼$62.74$867.03M-2.37860,140 shs949,763 shsSLRNAcelyrin$2.43-5.8%$2.40$1.85▼$7.25$244.73M1.121.22 million shs1.42 million shsSYRESpyre Therapeutics$12.79-8.6%$19.85$12.56▼$40.84$770.69M3.05567,896 shs1.64 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-6.69%-11.30%-12.05%-23.46%+0.54%GPCRStructure Therapeutics-7.41%-23.52%-33.01%-45.53%-62.26%SLRNAcelyrin-5.81%-6.54%-5.45%-36.39%-63.35%SYRESpyre Therapeutics-8.58%-28.71%-34.31%-47.47%-63.10%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELVNEnliven Therapeutics2.4551 of 5 stars3.61.00.00.03.24.20.0GPCRStructure Therapeutics2.0031 of 5 stars3.51.00.00.03.11.70.6SLRNAcelyrin2.8909 of 5 stars3.22.00.00.03.33.31.3SYRESpyre Therapeutics1.7919 of 5 stars3.60.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 3.20Buy$38.75107.33% UpsideGPCRStructure Therapeutics 3.00Buy$81.29437.60% UpsideSLRNAcelyrin 2.40Hold$9.60295.06% UpsideSYRESpyre Therapeutics 3.13Buy$50.33293.54% UpsideCurrent Analyst Ratings BreakdownLatest SLRN, GPCR, SYRE, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.003/18/2025SYRESpyre TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$27.002/28/2025GPCRStructure TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform2/18/2025SYRESpyre TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/13/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.001/8/2025GPCRStructure TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.001/7/2025SLRNAcelyrinCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $3.001/7/2025SLRNAcelyrinHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $6.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/ASLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ASYRESpyre Therapeutics$890K865.94N/AN/A($0.22) per share-58.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)GPCRStructure Therapeutics-$89.62M-$0.79N/AN/AN/AN/A-16.37%-15.68%5/8/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.50N/AN/AN/AN/A-44.12%-39.02%5/13/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$4.23N/AN/AN/AN/A-210.01%-44.40%5/8/2025 (Estimated)Latest SLRN, GPCR, SYRE, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2025Q4 2024SLRNAcelyrin-$0.86-$0.79+$0.07-$0.79N/AN/A3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million2/27/2025Q4 2024GPCRStructure Therapeutics-$0.23-$0.22+$0.01-$0.22N/AN/A2/27/2025Q4 2024SYRESpyre Therapeutics-$0.89-$0.81+$0.08-$0.81$2.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A17.4417.44GPCRStructure TherapeuticsN/A27.6327.63SLRNAcelyrinN/A7.157.15SYRESpyre TherapeuticsN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%GPCRStructure Therapeutics91.78%SLRNAcelyrin87.31%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics29.20%GPCRStructure Therapeutics9.43%SLRNAcelyrin13.60%SYRESpyre Therapeutics6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5049.00 million34.59 millionOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableSLRNAcelyrin135100.71 million86.68 millionOptionableSYRESpyre Therapeutics10060.26 million48.24 millionOptionableSLRN, GPCR, SYRE, and ELVN HeadlinesRecent News About These CompaniesSpyre Therapeutics Announces Grants of Inducement AwardsApril 4 at 4:05 PM | prnewswire.comPictet Asset Management Holding SA Buys 266,418 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)April 2 at 4:30 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week Low - Time to Sell?April 2 at 4:11 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 7.7% - Here's What HappenedApril 1, 2025 | marketbeat.comSwiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 30, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's WhyMarch 29, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyMarch 28, 2025 | finanznachrichten.deSpyre Therapeutics (NASDAQ:SYRE) Shares Up 5.2% - Still a Buy?March 28, 2025 | marketbeat.comNatixis Advisors LLC Purchases Shares of 17,300 Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 28, 2025 | marketbeat.comAptorum Group (NASDAQ:APM) vs. Spyre Therapeutics (NASDAQ:SYRE) Head to Head SurveyMarch 28, 2025 | americanbankingnews.comSpyre Therapeutics says first patient dosed in Phase 1 trial of SPY003March 27, 2025 | markets.businessinsider.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's WhyMarch 27, 2025 | marketbeat.comSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyMarch 27, 2025 | prnewswire.comEFG Asset Management North America Corp. Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 27, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 6.4% - Here's What HappenedMarch 26, 2025 | marketbeat.comEmerald Advisers LLC Acquires 254,222 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 24, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)March 23, 2025 | marketbeat.comCommit To Buy Spyre Therapeutics At $12.50, Earn 13.5% Annualized Using OptionsMarch 21, 2025 | nasdaq.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?March 19, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Coverage Initiated at Wolfe ResearchMarch 19, 2025 | marketbeat.comSpyre Therapeutics initiated with an Outperform at Wolfe ResearchMarch 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLRN, GPCR, SYRE, and ELVN Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$18.69 -1.34 (-6.69%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$18.68 -0.01 (-0.05%) As of 04/4/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Structure Therapeutics NASDAQ:GPCR$15.12 -1.21 (-7.41%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$15.51 +0.39 (+2.59%) As of 04/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Acelyrin NASDAQ:SLRN$2.43 -0.15 (-5.81%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$2.52 +0.09 (+3.70%) As of 04/4/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Spyre Therapeutics NASDAQ:SYRE$12.79 -1.20 (-8.58%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$12.75 -0.04 (-0.31%) As of 04/4/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
